Trial record 1 of 1 for:
PANBELA CL-SBP-101-04 (ASPIRE)
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05254171 |
Recruitment Status :
Recruiting
First Posted : February 24, 2022
Last Update Posted : April 16, 2024
|
Sponsor:
Panbela Therapeutics, Inc.
Information provided by (Responsible Party):
Panbela Therapeutics, Inc.
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | January 13, 2022 | ||||||||
First Posted Date ICMJE | February 24, 2022 | ||||||||
Last Update Posted Date | April 16, 2024 | ||||||||
Actual Study Start Date ICMJE | August 8, 2022 | ||||||||
Estimated Primary Completion Date | August 29, 2026 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
Overall Survival (OS) [ Time Frame: From date of first dose up to 100 weeks or until death ] Compare OS between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combination with nab-paclitaxel and gemcitabine
|
||||||||
Original Primary Outcome Measures ICMJE |
Overall Survival (OS) [ Time Frame: Randomization (Day 1) until death from any cause assessed up to 36 months ] Compare OS between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combination with nab-paclitaxel and gemcitabine
|
||||||||
Change History | |||||||||
Current Secondary Outcome Measures ICMJE |
Progression Free Survival (PFS) [ Time Frame: From date of first dose up to 100 weeks or until death ] Compare PFS between SBP-101 and placebo
|
||||||||
Original Secondary Outcome Measures ICMJE |
Progression Free Survival (PFS) [ Time Frame: Randomization (Day 1) until disease progression or death from any cause, whichever occurs first, assessed up to 36 months ] Compare PFS between SBP-101 and placebo
|
||||||||
Current Other Pre-specified Outcome Measures |
|
||||||||
Original Other Pre-specified Outcome Measures |
|
||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | ||||||||
Official Title ICMJE | A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma | ||||||||
Brief Summary | The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment. | ||||||||
Detailed Description | This trial will enroll approximately 600 patients to evaluate the effect of SBP-101 on Overall Survival when administered with gemcitabine and nab-paclitaxel compared to gemcitabine and nab-paclitaxel and a placebo. Secondary endpoints include Progression-free survival, radiologic responses to treatment, and Quality of Life measures. An independent, external Data Safety Monitoring Board (DSMB) will monitor safety and efficacy and a planned futility analysis. | ||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase ICMJE | Phase 2 Phase 3 |
||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: 1:1 randomization to Experimental Arm vs. Control Arm Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment |
||||||||
Condition ICMJE |
|
||||||||
Intervention ICMJE |
|
||||||||
Study Arms ICMJE |
|
||||||||
Publications * | Not Provided | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE |
600 | ||||||||
Original Estimated Enrollment ICMJE |
150 | ||||||||
Estimated Study Completion Date ICMJE | January 1, 2027 | ||||||||
Estimated Primary Completion Date | August 29, 2026 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Sex/Gender ICMJE |
|
||||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||
Contacts ICMJE |
|
||||||||
Listed Location Countries ICMJE | Australia, Austria, Belgium, France, Germany, Italy, Korea, Republic of, Spain, United Kingdom, United States | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT05254171 | ||||||||
Other Study ID Numbers ICMJE | CL-SBP-101-04 | ||||||||
Has Data Monitoring Committee | Yes | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement ICMJE |
|
||||||||
Current Responsible Party | Panbela Therapeutics, Inc. | ||||||||
Original Responsible Party | Same as current | ||||||||
Current Study Sponsor ICMJE | Panbela Therapeutics, Inc. | ||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||
Collaborators ICMJE | Not Provided | ||||||||
Investigators ICMJE |
|
||||||||
PRS Account | Panbela Therapeutics, Inc. | ||||||||
Verification Date | April 2024 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |